Abstract
Although new passive and active immunotherapy methods are emerging, unconjugated monoclonal antibodies remain the only kind of biological preparations approved for high-grade glioma therapy in clinical practice. In this review, we combine clinical and experimental data discussion. As antiangiogenic therapy is the standard of care for recurrent glioblastoma multiforme (GBM), we analyze major clinical trials and possible therapeutic combinations of bevacizumab, the most common monoclonal antibody to vascular endothelial growth factor (VEGF). Another humanized antibody to gain recognition in GBM is epidermal growth factor (EGFR) antagonist nimotuzumab. Other antigens (VEGF receptor, platelet-derived growth factor receptor, hepatocyte growth factor and c-Met system) showed significance in gliomas and were used to create monoclonal antibodies applied in different malignant tumors. We assess the role of genetic markers (isocitrate dehydrogenase, O6-methylguanine-DNA methyltransnsferase) in GBM treatment outcome prediction. Besides antibodies studied in clinical trials, we focus on perspective targets and briefly list other means of passive immunotherapy.
Keywords: Angiogenesis, bevacizumab, glioma, monoclonal antibodies, nimotuzumab, passive immunotherapy.
Current Cancer Therapy Reviews
Title:Trends in Malignant Glioma Monoclonal Antibody Therapy
Volume: 11 Issue: 2
Author(s): Ivan Chekhonin and Olga Gurina
Affiliation:
Keywords: Angiogenesis, bevacizumab, glioma, monoclonal antibodies, nimotuzumab, passive immunotherapy.
Abstract: Although new passive and active immunotherapy methods are emerging, unconjugated monoclonal antibodies remain the only kind of biological preparations approved for high-grade glioma therapy in clinical practice. In this review, we combine clinical and experimental data discussion. As antiangiogenic therapy is the standard of care for recurrent glioblastoma multiforme (GBM), we analyze major clinical trials and possible therapeutic combinations of bevacizumab, the most common monoclonal antibody to vascular endothelial growth factor (VEGF). Another humanized antibody to gain recognition in GBM is epidermal growth factor (EGFR) antagonist nimotuzumab. Other antigens (VEGF receptor, platelet-derived growth factor receptor, hepatocyte growth factor and c-Met system) showed significance in gliomas and were used to create monoclonal antibodies applied in different malignant tumors. We assess the role of genetic markers (isocitrate dehydrogenase, O6-methylguanine-DNA methyltransnsferase) in GBM treatment outcome prediction. Besides antibodies studied in clinical trials, we focus on perspective targets and briefly list other means of passive immunotherapy.
Export Options
About this article
Cite this article as:
Chekhonin Ivan and Gurina Olga, Trends in Malignant Glioma Monoclonal Antibody Therapy, Current Cancer Therapy Reviews 2015; 11 (2) . https://dx.doi.org/10.2174/1573394711888150917142941
DOI https://dx.doi.org/10.2174/1573394711888150917142941 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Contrasting Roles of NKT Cells in Tumor Immunity
Current Molecular Medicine Targeting the Eph System with Peptides and Peptide Conjugates
Current Drug Targets Co-targeting EGFR and Autophagy Impairs Ovarian Cancer Cell Survival during Detachment from the ECM
Current Cancer Drug Targets Atypical PKCι as Target for Glioblastoma Therapy
Current Cancer Drug Targets Crossed Cerebellar Diaschisis in Alzheimer’s Disease
Current Alzheimer Research ADAM8/MS2/CD156, an Emerging Drug Target in the Treatment of Inflammatory and Invasive Pathologies
Current Pharmaceutical Design Targeting the Akt/PI3K Signaling Pathway as a Potential Therapeutic Strategy for the Treatment of Pancreatic Cancer
Current Medicinal Chemistry Oxidative Stress and Cancer: The Role of Nrf2
Current Cancer Drug Targets Anticancer Peptides and Proteins: A Panoramic View
Protein & Peptide Letters State of Art and Recent Developments of Anti-Cancer Strategies Based on TRAIL
Recent Patents on Anti-Cancer Drug Discovery A Fluorescent Alkyllysophospholipid Analog Exhibits Selective Cytotoxicity Against the Hormone-Insensitive Prostate Cancer Cell Line PC3
Anti-Cancer Agents in Medicinal Chemistry Preoperative Functional Magnetic Resonance Imaging (fMRI) and Transcranial Magnetic Stimulation (TMS)
Current Medical Imaging Hepatoma-Derived Growth Factor in Carcinogenesis and Cancer Progression
Current Drug Therapy The Role of Mammalian Target of Rapamycin (mTOR) Inhibitors in the Treatment of Solid Tumors
Current Cancer Therapy Reviews Cyclooxygenase-2: Potential Role in Regulation of Drug Efflux and Multidrug Resistance Phenotype
Current Pharmaceutical Design The Disposal of Reactive Carbonyl Species through Carnosine Conjugation: What We Know Now
Current Medicinal Chemistry The Synergistic Cytotoxic and Apoptotic Effect of Resveratrol and Naringenin on Y79 Retinoblastoma Cell Line
Anti-Cancer Agents in Medicinal Chemistry Phosphonium Salt Displays Cytotoxic Effects Against Human Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Toll-Like Receptors: Cost or Benefit for Cancer?
Current Pharmaceutical Design Endothelial Cell Heterogeneity: A Developmental Biologist’s Perspective
Current Angiogenesis (Discontinued)